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Abstract
Background: Cardiovascular secondary preventive recommendations are often not reached. We investigated
whether a nurse-led telephone-based follow-up could improve the implementation of a new guideline within a
year after its release.
Methods: In February 2013, a new secondary preventive guideline for diabetic patients was released in the
county of Jämtland, Sweden. It included a changed of the low-density lipoprotein cholesterol (LDL-C) target
value from <2.5 mmol/L to <1.8 mmol/L. In the Nurse-Based Age-Independent Intervention to Limit Evolution of Disease
(NAILED) trial, patients with an acute coronary syndrome, stroke, or transient ischemic attack were randomized to
secondary preventive care with nurse-based telephone follow-up (intervention) or usual care (control). Patient data were
obtained from the NAILED trial to study the implementation of the new LDL-C guideline by comparing telephone
follow-up with usual care. The Mann–Whitney U-test was used for continuous variables, and Person’s χ2 test was
used for categorical variables to assess between-group differences.
Results: Out of the 1267 patients that entered the study period, 101 intervention and 100 control patients with diabetes
fulfilled the inclusion criteria and completed the study period. Before the guideline change, 96 % of the intervention
patients and 70 % of the control patients reached the target LDL-C value (p < 0.001). After the guideline change, the
corresponding respective proportions were 65 % and 36 % (p < 0.001). The main reason that intervention patients did
not achieve the target LDL-C value was that they received full-dose treatment; for control patients, the main reason was
that medication was not adjusted, for an unknown reason.
Conclusions: One year after a change in the cardiovascular secondary preventive guideline, nurse-based telephone
follow-up performed better than usual care to implement the new recommendation.
Trial registration: ISRCTN registry; ISRCTN96595458 (date of registration 10 July 2011) and ISRCTN23868518
(date of registration 13 May 2012).
Keywords: Acute coronary syndrome, Cardiovascular disease, Myocardial infarction, Randomized controlled trial,
Secondary prevention, Stroke, Transient ischemic attack
Background
Treatment of modifiable risk factors after a cardiovascular
event is of great importance. The combination of different
therapies can reduce the risk of subsequent events
substantially [1]. Consequently, treatment guidelines
for secondary prevention in patients with established
cardiovascular disease (CVD) have been published,
addressing the CVD population in general, as well as
different subsets of patients with specific comorbidi-
ties. As evidence emerges to support new treatment
strategies, international, national, and local updates of
these guidelines are frequently released [2–5]. In general,
physicians seem to have positive attitudes towards
guidelines, and the self-reported adherence is high [6–8].
However, previous investigations of CVD patients’ modifi-
able risk factors have found that treatment goals according
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to guidelines are often not reached; consequently,
optimum risk reduction is not achieved [9–12]. These pre-
vious studies investigated adherence to guidelines at a
substantial interval after they had been released, and less
is known about adherence during the first year after
guideline release. Knowledge about guideline implementa-
tion is important, because rapid adjustment provides an
opportunity to reduce the risk of recurrent events.
In Sweden, the general practitioner (GP) usually man-
ages secondary preventive follow-up after hospital care for
a cardiovascular event. Local guidelines for the treatment
of diabetic patients in primary health care in the county of
Jämtland, Sweden, were changed in February 2013. A GP
was responsible for the revision of the guidelines, and a
new recommendation was included regarding low-density
lipoprotein cholesterol (LDL-C) for diabetic patients
with established CVD. To better agree with the
European guidelines [3], the target level was lowered
from LDL-C <2.5 mmol/L to <1.8 mmol/L.
The Nurse-Based Age-Independent Intervention to
Limit Evolution of Disease after Acute Coronary Syn-
drome (NAILED ACS) and the NAILED stroke risk factor
trials are ongoing randomized controlled trials in the
county of Jämtland. Their objective is to improve second-
ary prevention after acute coronary syndrome (ACS),
stroke, and transient ischemic attack (TIA) through a
nurse-based telephone follow-up concerning cardiovascu-
lar risk factors. Different organizational strategies have
previously been evaluated to improve secondary prevent-
ive care (e.g., patient education, physician education, pre-
booked doctor appointments, etc.), most of which have
not proven effective with respect to risk factor reduction
[13, 14]. There are some exceptions to this, including
some support for telephone-based follow-up to improve
risk factor control [15, 16]. The aim of this report was to
describe the implementation of new cardiovascular
guidelines in primary care and to compare it with the
performance of the follow-up in the NAILED study. We
hypothesized that the proportion of patients that reached
the target LDL-C value the year after the guideline change
would decrease, and that a greater proportion of patients
randomized to nurse-based, telephone follow-up would
reach the new recommended levels of LDL-C, compared
with patients randomized to usual care.
Methods
The study was approved by the Regional Ethics Committee,
Umeå University (reference number Dnr-09-142 M). Pa-
tient data were obtained from the ongoing randomized,
controlled NAILED trials with the aim to improve patients’
blood pressure and LDL-C values. A detailed description of
the rationale and design of the NAILED trails has been
published [17, 18]. In brief, all patients living in the county
of Jämtland, Sweden who are hospitalized with a diagnosis
of myocardial infarction, unstable angina, stroke, or TIA
are assessed for inclusion. Östersund Hospital is the only
hospital in the county; it has a rural catchment area, with a
population of approximately 125,000 inhabitants. Study
nurses identified eligible patients with the physical and
mental capacity to communicate by telephone. Patients
with deafness, aphasia, dementia, or severe (often terminal)
diseases were not included. Participants in other ongoing
trials were also excluded. All eligible patients were informed
about the study, and those who agreed to participate were
randomized to intervention or control in a 1:1 ratio.
Patient characteristics, including medical history,
were recorded during the initial hospitalization. At
1 month after discharge, baseline measurements of
blood lipids and blood pressure (BP) were performed.
Corresponding follow-up measurements were per-
formed annually thereafter.
Shortly after the baseline blood lipid and BP measure-
ments, participants in both study groups were contacted
by a study nurse by telephone and interviewed about
their wellbeing and adherence to medical treatment. In
the control group, LDL-C and BP values were forwarded
directly to the patient’s GP for assessment, without
further action from the study team. For patients ran-
domized to intervention who did not reach the target
values for LDL-C and/or BP, medication titration was
made. Tests were repeated within approximately 4 weeks,
and additional medication titration was performed if ne-
cessary until target values were reached or no additional
changes were considered reasonable. A study physician
made decisions regarding titration and medication.
On 14 February 2013, information about a local guide-
line change regarding target LDL-C value for patients
with diabetes mellitus (DM) and established CVD was
distributed to all GPs through a joint e-mail group,
which is used for spreading information that concerns pri-
mary health care in Jämtland. As stated above, the target
value for LDL-C was lowered from LDL-C <2.5 mmol/L
to LDL-C <1.8 mmol/L, in accordance with the European
Society of Cardiology’s guidelines [3]. The same LDL-C
target value was adopted 24 March 2013 by the
NAILED trial, in order to follow the same guidelines
as primary care. No extra follow-up was performed
within the NAILED studies because of the guideline
change, and the scheduled follow-up according to the
study protocol remained the same. All diabetic pa-
tients in the NAILED trial database who received a
telephone follow-up call before 14 February 2013 (any
of 1 month or 1, 2, or 3 years after the initial
hospitalization) and another follow-up call after 31
March 2013 and before 16 June 2014 were included
in the analysis. We chose to study the implementation of
the new guideline after 31 March 2013 to give all the
study nurses a chance to receive the new information. The
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end date of follow-up was set to 15 June 2014, to make
sure that all patients had one follow-up and that medica-
tion titrations, if any, had been completed.
Baseline characteristics in the current analysis were
those reported at the most recent follow-up within the
NAILED-trial before 14 February 2013. Patients were
considered to have DM if they received glucose lowering
medication or dietary treatment at the follow-up after 31
March 2013. If a patient reached LDL-C <1.8 mmol/L at
follow-up, that value was reported as the end-point
LDL-C. For patients in the intervention group who did
not achieve the target LDL-C value, the value reached
after medication titration was reported as the end-point
LDL-C value. The patient records were scrutinized for
those patients in the control group who did not reach
target value at the first follow-up after 31 March 2013,
in order to determine whether the GP took notice of the
elevated LDL-C value, and if so, whether any medication
titration was performed. In Jämtland, the standard of
care for diabetic patients includes a yearly visit to their
GP. During this visit, local guidelines state that risk
factor control and intervention regarding established risk
factors for CVD is performed. This includes laboratory
measurements of serum levels of glucose and lipids, as
well as clinical examination including BP control. If no
patient record could be found that mentioned the LDL-
C value within 1 month after the NAILED-control, then
we used the LDL-C value recorded at the first yearly
diabetes control after 31 March 2013. If the GP titrated
any medication, the value after titration was used. If no
patient record was found regarding LDL-C values and
no yearly diabetes control had been performed before
the end date for the present study, 15 June 2014 (n = 8),
the LDL-C value at the NAILED trial follow-up was
reported. Atorvastatin 80 mg or rosuvastatin 40 mg,
with or without ezetimib 10 mg, was considered full-
dose treatment.
Statistical analysis
The results are presented as median and percentiles for
continuous variables and as percentages for categorical
variables. The Mann–Whitney U-test was used for
continuous variables since the data was not normally
distributed, and Person’s χ2 test was used for categorical
variables to assess between-group differences. The
Wilcoxon signed rank test was used to study the change
in LDL-C before and after the guideline change. P < 0.05
was considered statistically significant. Statistical
analyses were performed using SPSS 20.0 software.
Results
Two hundred and one ACS, stroke, or TIA patients had
at least one follow-up call before 14 February 2013, a
follow-up after 31 March 2013 and had diabetes. Of
these, 101 patients had been randomized to the inter-
vention and 100 to the control group (Fig. 1). Baseline
characteristics are shown in Table 1. The intervention
and control groups were well matched except for the
cholesterol values and BP (i.e., the variables under inter-
vention in the NAILED study). The intervention group
contained significantly more patients with ACS than
stroke as the qualifying event than the control group.
The randomization process was stratified for ACS and
stroke/TIA, but not for diabetes status. The difference in
the proportion of ACS patients between the intervention
and control groups in the DM cohort was seen already
at randomization (75 patients with DM and ACS in the
intervention group and 61 in the control group; 53 pa-
tients with DM and stroke or TIA in the intervention
group and 63 to the control group). The difference
between the proportions of ACS and stroke/TIA patients
in the DM intervention group was further enhanced by
more new cases of diabetes among those with prior
ACS (n = 12) than among those with a prior stroke or
TIA (n = 1) who were randomized to intervention.
Among those randomized to the control group the
number of new diabetes cases was fairly similar
among those with a prior stroke or TIA (n = 8) or a
prior ACS (n = 6).
Lipid-lowering treatments after the introduction of the
new guideline (before and after titration of medication)
are shown in Table 2. In the intervention group, 39.6 %
of patients had at least one medication titration. In
comparison, 9.0 % of control patients had one or several
medication titrations (p < 0.001).
The median LDL-C value before the guideline change
from LDL-C <2.5 mmol/L was 1.9 mmol/L in the
intervention group and 2.1 mmol/L in the control
group (p < 0.001). After the introduction of the new
target LDL-C value (<1.8 mmol/L) the median values
in intervention and control patients were 1.7 mmol/L
and 2.0 mmol/L, respectively (p < 0.001). The LDL-C
value decreased significantly in the intervention group
(p = 0.03), but not in the control group (p = 0.77).
Figure 2 shows the proportion of patients that reached
the target value before and after the guideline change.
Before the change, 96.0 % of intervention patients and
70.0 % of control patients reached the target LDL-C
value of <2.5 mmol/L (p < 0.001). After the change to
the new LDL-C target (<1.8 mmol/L), the corresponding
proportions of patients were 65.3 and 36.0 %, respect-
ively (p < 0.001).
Thirty-five intervention patients and 64 control patients
did not reach LDL-C <1.8 mmol/L after the change in the
guideline. In the intervention group, the main reasons for
failing were that patients were on full-dose treatment
(37.1 %) or no intervention was performed for an
unknown reason (20.0 %). For control patients, the main
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Fig. 1 Study flow chart. *If necessary, medication was titrated until target values were reached or until no further changes were considered
reasonable. Jan, January; Feb, February; n, number of cases; Mar, March; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol
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Table 1 Baseline characteristics
Intervention (n = 101) Control (n = 100) P-value
Age, years 72 (66–80) 73 (66–79) 0.99
Women (%) 27.7 30.0 0.72
Smoking (%) 4.0 6.0 0.51
Self-reported healtha 70 (50–85) 70 (50–80) 0.70
Prior cardiovascular diseaseb 38.6 42.0 0.63
HbA1c, mmol/mol 58 (50–70) 57 (51–65) 0.36
Weight, kilograms 85 (75–97) 86 (76–97) 1.0
Waist, centimeters 103 (95–111) 105 (96–112) 0.55
Systolic blood pressure, mmHg 128 (120–133) 134 (124–145) <0.001
Diastolic blood pressure, mmHg 70 (65–80) 76 (70–82) 0.005
Cholesterol, mmol/L 3.7 (3.4–4.0) 4.1 (3.6–4.6) <0.001
LDL-C, mmol/L 1.9 (1.5–2.0) 2.1 (1.6–2.5) <0.001
HDL-C, mmol/L 1.20 (0.98–1.39) 1.18 (0.97–1.48) 0.88
Triglycerides, mmol/L 1.4 (1.0–1.9) 1.5 (1.2–2.2) 0.06
Study, ACSc (%) 64.4 47.0 0.01
No lipid lowering treatment (%) 9.9 12.0 0.63
Simvastatin (%) 47.5 54.0 0.36
Atorvastatin (%) 36.6 32.0 0.49
Other lipid lowering strategyd (%) 5.9 1.0 0.06
If not other specified, values are reported as median (25th–75th percentiles)
LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; ACS, acute coronary syndrome
aSelf-reported health between 0–100
bPrevious myocardial infarction, angina pectoris, stroke or peripheral artery disease
cPatient included in the study due to ACS or stroke/TIA
dRosuvastatin, combination of rosuvastatin and ezetimib or gemfibrozil
Table 2 Lipid lowering treatments after the guideline change
Before medication titration After medication titration
Intervention Control P-value Intervention Control P-value
No treatment (%) 12.9 11.0 0.68 4.0 9.0 0.15
Simvastatin (%) 33.7 52.0 0.009 21.8 51.0 <0.001
Simvastatin 10 mg 2.0 5.0 0.24 1.0 6.0 0.05
Simvastatin 20 mg 14.9 25.0 0.07 9.9 21.0 0.03
Simvastatin 40 mg 16.8 22.0 0.35 10.9 24.0 0.01
Atorvastatin (%) 44.6 35.0 0.17 56.4 38.0 0.009
Atorvastatin 20 mg 6.9 13.0 0.15 5.0 14.0 0.03
Atorvastatin 40 mg 25.7 19.0 0.25 29.7 21.0 0.16
Atorvastatin 60 mg 0 1.0 0.31 0 1.0 0.31
Atorvastatin 80 mg 11.9 2.0 0.006 22.8 2.0 <0.001
Rosuvastatin (%) 4.0 0 0.04 8.9 0 0.002
Rosuvastatin 20 mg 3.0 0 0.08 3.0 0 0.08
Rosuvastatin 40 mg 1.0 0 0.32 5.9 0 0.01
Othera (%) 5.0 2.0 0.25 7.9 2.0 0.05
aPravastatin 40 mg, combination of atorvastatin 80 mg and ezetimib 10 mg or combination of rosuvastatin 40 mg and ezetimib 10 mg
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reasons for not reaching target value were that no inter-
vention was performed (76.6 %) or that intervention was
performed but target value was not reached (10.9 %). All of
the reported reasons for not reaching LDL-C <1.8 mmol/L
after the guideline change are shown in Fig. 3.
Discussion
To the authors’ knowledge, this is the first study to assess
the early effect on implementation of a new secondary
preventive guideline for patients with established CVD
and compares a structured, nurse-based intervention with
usual care according to current practice. We have shown
that, compared with usual care, a secondary preventive,
nurse-based telephone follow-up increased the proportion
of patients that reached the target level of LDL-C during
the first year after a guideline change. The main reason
for failing to reach the target value in the intervention
group was that the maximal statin dose had been reached.
Regarding the vast majority of patients in the usual care
group who did not reach the target, no reason was found
in their medical records.
Different organizational strategies to improve second-
ary preventive care for patients with established CVD
have been evaluated in previous studies; two recent
Cochrane reviews lacked clearly positive results [13, 14].
A key methodological difference between the trials
included in the meta-analyses and the method used in
the NAILED trial was the prompt titration of medication
by a study physician when patients’ LDL-C levels were
above target. One meta-analysis that compared different
organizational strategies to improve glycemic control in
diabetic patients found that the greatest reduction
occurred in trials in which case managers were able to
adjust medications promptly [19]. McAlister et al. also
found that case management after ischemic stroke with
active prescribing by a pharmacist improved the control
of LDL-C compared with nurse-led screening and feed-
back to the GP [15].
Trials that evaluated telephone follow-up as a part of
secondary preventive care have shown some positive
results regarding the control of modifiable risk factors.
However, these studies had rigorous protocols, ambi-
tious patient information packages, and frequent patient
support, which may have limited their applicability in
clinical practice [20–22]. The NAILED trial employed a
simplified, nurse-based telephone follow-up protocol. A
method for yearly follow-up of modifiable risk factors
must be cost-effective, as well as easy to implement
throughout healthcare organizations. The simplified
NAILED method makes it possible to include a large
proportion of eligible patients. For example, living in
rural areas is not an obstacle to receiving follow-up by
telephone. Furthermore, the median age in the present
study was over 70 years, which shows that telephone
follow-up according to the NAILED trial can be imple-
mented in an aged patient population with considerable
Fig. 2 Proportion of patients that achieved the target LDL-C value
before and after the guideline change. *The target value at the time
being investigated. LDL-C, low-density lipoprotein cholesterol
Fig. 3 Reported reasons for not reaching the target LDL-C value. *No reason was reported for not performing any intervention
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comorbidity. In comparison, the mean age of partici-
pants in the previously mentioned telephone follow-up
trials was between 59 and 65 years [20–22].
Even though the nurse-based telephone follow-up
performed better than usual care, there were still fewer
patients in both intervention and control groups who
reached the target LDL-C value after the guideline
change. In the intervention group, the main reason for
not reaching the target LDL-C value was that patients
were considered to have full dose treatment. This find-
ing emphasizes that even if patients received atorvastatin
80 mg or rosuvastatin 40 mg, as well as dietary and
exercise advice, some patients cannot reach desirable
LDL-C values with the treatment options available today.
Recently reported results about the effect of adding
ezetimibe or PCSK9 inhibitors to statin treatment indi-
cate that the proportion of patients in whom an LDL-C
level <1.8 mmol/L can be reached will increase [23, 24].
The intervention patients’ test results were screened
by a trained study nurse whose main focus was to ensure
that the patients’ risk factors were at a desirable level,
and was otherwise supposed to notify a study physician.
Despite this, 7/35 (20.0 %) intervention patients who did
not reach the LDL-C target received no intervention for
an unknown reason. Hence, even under controlled
conditions, optimal treatment of risk factors is difficult
to achieve, largely because of human factors.
For patients in the control group, the main reason for
not reaching the LDL-C target was that the treating
physician did not actively intervene to improve LDL-C
levels, for an unknown reason. Possible causes for the
physicians’ lack of action include lack of time, lack of
patient adherence, lack of guideline knowledge, and
differing opinions about target value compared with
guidelines. These have all been suggested as reasons for
not adhering to guidelines in previous studies [8, 25].
Other possibilities could be that the treating physician
had forgotten about the new guideline or had not read
the information about the guideline change, both of
which could be a result of the abundance of guidelines
directed to GPs [26].
There were very few cases of adverse effects being
reported as the cause for not reaching the target LDL-C
value. In the intervention group, this can probably be
explained by flexible medication; using different doses and
different statins made it possible to overcome many of the
perceived adverse effects [27, 28]. In the control group,
one possible reason is that patients have previously re-
ported adverse effects caused by lipid-lowering treatments;
however, this reason was not found in the medical records
reviewed. This would be reported as “No intervention”.
The intervention group contained significantly more
patients with ACS than stroke as the qualifying event
than the control group. This difference was present
already at randomization and was then further increased
by more new cases of diabetes in the intervention group
among those with prior ACS and in the control group
among those with a prior stroke or TIA. Consequently,
the unequal distribution of patients with ACS between
the intervention and control groups seems to be caused
by the play of chance.
Our results lead us to believe that a number of compo-
nents are needed to achieve adequate implementation of
(and optimal adherence to) recommended secondary pre-
ventive guidelines; a structured method, comparable with
the NAILED method; a procedure for rapid medication
titration to reach target values to the greatest extent
possible; a system with a control mechanism to ensure
that no patients are missed and that the treatment is in-
tensified as needed; and finally, different pharmacological
options, in order to overcome potential adverse effects.
Limitations
This study has some limitations. First of all, the patients
who chose to participate in the study might have been
more motivated to follow secondary preventive advice
than those who declined. Second, we cannot rule out that
the study setting influenced the secondary preventive care
provided to the control group. The study team provided
the GPs with LDL-C measurements that might not have
been performed otherwise. Furthermore, it is possible that
patients, by participating in the study, became more prone
to contact their GP for secondary preventive assessment.
The possible influence on the control group (simply by
participating in a study) and the LDL-C measurements
according to the study protocol may have led to an under-
estimation of the intervention effect. Third, regarding
reasons for not reaching the target LDL-C value,
documentation in the NAILED trial is less extensive for
the control group than for the intervention group. The
GPs who received test results from the NAILED follow-up
had to sign them, but may not have documented any
conclusions in the patients’ records.
Conclusion
In this study, we have shown that during the first year
after the introduction of a new cardiovascular secondary
preventive guideline defining a lower LDL-C target
value, fewer patients reached target regardless of nurse-
based telephone follow-up or usual care. However,
nurse-based telephone follow-up performed better than
usual care, and the large proportion of LDL-C values
above target in the intervention group was explained by
inadequate treatment effect despite full-dose medication.
This supports the hypothesis that nurse-based telephone
follow-up according to the NAILED trial is an effective
way to improve secondary preventive care after a cardio-
vascular event.
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